Hepatitis C virus and eliminating post-transfusion hepatitis

Nature Medicine

Volumn 6, Issue 10, 2000, Pages 1082-1086

  Alter, Harvey J ^a   Houghton, Michael ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN;

BLOOD DONOR; BLOOD TRANSFUSION; HEPATITIS B; HEPATITIS C VIRUS; HUMAN; INCIDENCE; NOTE; PRIORITY JOURNAL; VIRUS INACTIVATION; VIRUS TRANSMISSION; ARTICLE; AWARDS AND PRIZES; DISEASE TRANSMISSION; HEPATITIS C; HISTORY; ISOLATION AND PURIFICATION; LITERATURE; UNITED STATES; VIRUS HEPATITIS;

AUTOBIOGRAPHY; AWARDS AND PRIZES; BLOOD TRANSFUSION; HEPACIVIRUS; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HISTORY, 20TH CENTURY; HUMANS; UNITED STATES;

EID: 0034294827     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/80394     Document Type: Note

References (39)

1. A 'new' antigen in leukemia sera
2. Further studies on a 'new' human isoprecipitin system (Australia antigen)
3. Posttransfusion hepatitis after exclusion of the commercial and hepatitis B antigen positive donor
4. Hepatitis A detection by immune electron microscopy of a virus-like antigen associated with acute illness
5. Transfusion-associated hepatitis not due to viral hepatitis type A or B
6. Transmissible agent in 'non-A, non-B' hepatitis
7. Transmission of HTLV-III Infection from human plasma to chimpanzees: An animal model for the acquired immunodeficiency syndrome
8. Inactivation of hepatitis b virus and non-a, non-b virus by chloroform
9. Determining the size of non-A, non-B hepatitis virus by filtration
10. Lack of protective immunity against reinfection with hepatitis C virus
11. Prevention of HCV infection in chimpanzees following antibody-mediated in vitro neutralization
12. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
13. Long-term mortality after transfusion-associated non-A, non-B hepatitis
14. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
15. The relationship of donor transaminase (ALT) to recipient hepatitis: Impact on blood transfusion services
16. Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood
17. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients: An analysis of the transfusion-transmitted viruses study
18. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis
19. Non-A, non-B hepatitis: Advances and unfulfilled expectations of the first decade
20. Transmission of non-A, non-B hepatitis from man to chimpanzee
21. Non-A, non-B hepatitis transmission in chimpanzees: A project of the transfusion-transmitted viruses study group
22. Non-A, non-B hepatitis: Ultrastructural evidence for two agents in experimentally infected chimpanzees
23. The agents of non-A non-B hepatitis
24. Efficient isolation of genes by using antibody probes
25. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
26. Genetic organisation and diversity of the hepatitis C virus
27. Viral heterogeneity of the hepatitis C virus
28. Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: Implications for development of antiviral agents and vaccines
29. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections
30. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
31. Discovery of non-A, non-B hepatitis and identification of its etiology
32. Epidemiology of hepatitis C: Geographical differences and temporal trends
33. Current therapy for chronic hepatitis C
34. Binding of hepatitis C virus to CD 81
35. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity anti response to interferon alpha therapy in chronic hepatitis C
36. Candidate cause identified of non-A, non-B hepatitis